The connection between weight loss medications and addiction reduction represents a potentially transformative discovery in ...
Shares of Eli Lilly climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk.
SURMOUNT-5’s results reflect those of multiple real-world studies, which have found that tirzepatide treatment results in ...
Eli Lilly's weight-loss drug Zepbound outperformed Novo Nordisk's Wegovy in a head-to-head trial, leading to a rise ...
Analysts see the market for GLP-1 weight loss treatments rising to around $70 billion over the next five years.
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
As the Biden administration is proposing drugs like Ozempic and Wegovy be covered by Medicare and Medicaid, Black people need ...
Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...
Eli Lilly and Co. said its weight-loss treatment Zepbound helped patients lose 47% more relative weight than competitor Novo ...
Brand companies who own GLP-1 products have been pushing the Food and Drug Administration (FDA) to limit their compounding. On August 28, 2024, ...
Yet at the annual meeting of the Menopause Society earlier this fall, researchers presented new evidence that hormone therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback